• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Centogene N.V.

    5/15/24 5:07:38 PM ET
    $CNTG
    Medical Specialities
    Health Care
    Get the next $CNTG alert in real time by email
    6-K 1 tm2414579d1_6k.htm FORM 6-K

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

      

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER
    PURSUANT TO RULE 13a-16 OR 15d-16
    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of May 2024

     

    Commission File Number 001-39124

     

    Centogene N.V.
    (Translation of registrant's name into English)

     

    Am Strande 7
    18055 Rostock

    Germany
    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F x      Form 40-F ¨

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

     

     

     

     

     

     

    Centogene N.V.

     

    Press Release Announcements

     

    Financial Results

     

    On May 15, 2024, Centogene N.V. (the “Company”) issued a press release reporting its financial results for the fourth quarter of 2023 and full year ended December 31, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

     

    Lifera Transactions

     

    On May 15, 2024, the Company issued a press release announcing its entry into certain transactions with Pharmaceutical Investment Company, a closed joint stock company incorporated pursuant to the laws of Saudi Arabia and trading as “Lifera” and a wholly-owned subsidiary of the Public Investment Fund based in Riyadh. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated by reference herein.

     

    Exhibits 99.1 and 99.2 to this Report on Form 6-K shall not be deemed “filed” for purposes of Section 18 of the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the U.S. Securities Act of 1933, as amended, or the Exchange Act.

     

    Convening of Annual General Meeting of Shareholders and Related Materials

     

    On May 15, 2024, the Company convened the annual general meeting of shareholders to be held on May 31, 2024, and made available to its shareholders certain other materials in connection with such meeting. Such materials are attached as Exhibits 99.3, 99.4, 99.5 and 99.6 to this Report on Form 6-K and are incorporated by reference herein.

     

    2

     

     

    Signatures

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Date: May 15, 2024

     

      CENTOGENE N.V.
         
      By: /s/ Jose Miguel Coego Rios 
        Name: Jose Miguel Coego Rios 
        Title: Chief Financial Officer

     

    3

     

     

    Exhibit Index

     

    Exhibit  Description of Exhibit
        
    99.1  Press Release regarding Financial Results, dated May 15, 2024.
        
    99.2  Press Release regarding Lifera Transactions, dated May 15, 2024.
        
    99.3  Convening Notice including Agenda and Explanatory Notes.
        
    99.4  Voting Proxy.
        
    99.5  Resolutions of the Management Board Centogene N.V.
        
    99.6  Resolutions of the Supervisory Board Centogene N.V.
        

    4

    Get the next $CNTG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CNTG

    DatePrice TargetRatingAnalyst
    8/5/2021$14.00Outperform
    Credit Suisse
    More analyst ratings

    $CNTG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CENTOGENE Closes Strategic Transaction with Private Equity Group Charme Capital Partners

      CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 12, 2025 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC:CNTGF) ("CENTOGENE" or the "Company") today announced it has closed its transaction to sell its operating subsidiaries to an affiliate of Charme Capital Partners Limited ("Charme"). As announced on November 13, 2024, the Company had entered into definitive agreements with Charme for the sale of 100% ownership in Centogene GmbH, CENTOGENE's sole operating subsidiary, certain intercompany receivables, and assumption of the Company's loan granted by Oxford Finance LLC (the "Transaction"). On December 4, 2024, the Company held an Extraordinary General Meeting ("EGM") in connection with th

      3/12/25 6:30:00 AM ET
      $CNTG
      Medical Specialities
      Health Care
    • CENTOGENE Announces Voting Results of Extraordinary General Meeting

      CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC:CNTGF) ("CENTOGENE" or the "Company"), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the voting results of the Company's Extraordinary General Meeting. Shareholders voted in favor of all proposals, which included the approval of the previously announced envisaged sale and transfer of Centogene GmbH to Charme Capital Partners Limited, a pan-European private equity firm. At the Extraordinary General Meeting of CENTOGENE, 57.16% of the Company's issued share capital were represented. About CENTOGENE CENTOGENE's mi

      12/4/24 7:51:01 PM ET
      $CNTG
      Medical Specialities
      Health Care
    • CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners

      CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC:CNTGF) ("CENTOGENE" or the "Company"), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced it has concluded its strategic review process and has entered into a Share Purchase Agreement ("SPA") pursuant to which its operating subsidiaries will be sold to an affiliate of Charme Capital Partners Limited ("Charme"), a pan-European private equity firm, for a cash purchase price of EUR 8,717,906.80. In connection with the transaction, Centogene GmbH will receive funding, secured by Saudi accounts receivables, from its Saudi Arabian

      11/13/24 6:30:01 AM ET
      $CNTG
      Medical Specialities
      Health Care

    $CNTG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Centogene N.V. (Amendment)

      SC 13D/A - Centogene N.V. (0001757097) (Subject)

      3/11/22 4:44:52 PM ET
      $CNTG
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by Centogene N.V. (Amendment)

      SC 13D/A - Centogene N.V. (0001757097) (Subject)

      2/22/22 4:00:59 PM ET
      $CNTG
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Centogene N.V.

      SC 13G - Centogene N.V. (0001757097) (Subject)

      12/8/21 8:52:19 PM ET
      $CNTG
      Medical Specialities
      Health Care

    $CNTG
    Financials

    Live finance-specific insights

    See more
    • CENTOGENE Reports Fourth Quarter and Full Year 2021 Financial Results

      - Full Year 2021 Total Revenue Growth of 48%, and 11% in Core Business Segments, Exceeds Guidance - Focus on Pharma and Diagnostics to Position for Strong Performance in 2022 - Closed $62 Million Financing Round and on Track to Exit COVID-19 Business - Management to Host Conference Call at 2 p.m. CET/8 a.m. ET Today CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 30, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced financial results for the fourth quarter and fiscal year ended December 31, 2021, and provided a business update. "2021 wa

      3/30/22 7:30:00 AM ET
      $CNTG
      Medical Specialities
      Health Care
    • CENTOGENE to Announce Fourth Quarter and Fiscal Year 2021 Financial Results on March 30, 2022

      CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced that it will issue its financial results for the quarter and full year ended December 31, 2021, on Wednesday, March 30, 2022, and will host a conference call and webcast to discuss these results at 2 p.m. CEST / 8 a.m. EDT that day. Participants may register in advance for the conference call and webcast to be held on March 30, 2022, at http://emea.directeventreg.com/registration/5737758. Upon registering, each participant will be provided w

      3/23/22 6:30:00 AM ET
      $CNTG
      Medical Specialities
      Health Care
    • CENTOGENE Reports Third Quarter 2021 Financial Results

      CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced financial results for the third quarter ended September 30, 2021, and provided a recent business update. Executive Commentary "We are encouraged by the progress achieved in Q3 on our continued path to return focus and growth to our rare disease business, driving strategic Core Business execution," stated Andrin Oswald, M.D., Chief Executive Officer at CENTOGENE. "We saw continued recovery trends in the Diagnostics segment, with over 40% incre

      11/24/21 7:35:47 AM ET
      $CNTG
      Medical Specialities
      Health Care

    $CNTG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Credit Suisse resumed coverage on Centogene with a new price target

      Credit Suisse resumed coverage of Centogene with a rating of Outperform and set a new price target of $14.00

      8/5/21 6:17:32 AM ET
      $CNTG
      Medical Specialities
      Health Care
    • Credit Suisse reiterated coverage on Centogene with a new price target

      Credit Suisse reiterated coverage of Centogene with a rating of Outperform and set a new price target of $14.00 from $15.00 previously

      6/17/21 7:44:42 AM ET
      $CNTG
      Medical Specialities
      Health Care

    $CNTG
    SEC Filings

    See more
    • SEC Form 6-K filed by Centogene N.V.

      6-K - Centogene N.V. (0001757097) (Filer)

      8/19/24 7:37:31 PM ET
      $CNTG
      Medical Specialities
      Health Care
    • SEC Form 6-K filed by Centogene N.V.

      6-K - Centogene N.V. (0001757097) (Filer)

      8/7/24 6:18:25 PM ET
      $CNTG
      Medical Specialities
      Health Care
    • SEC Form 6-K filed by Centogene N.V.

      6-K - Centogene N.V. (0001757097) (Filer)

      8/1/24 4:15:59 PM ET
      $CNTG
      Medical Specialities
      Health Care

    $CNTG
    Leadership Updates

    Live Leadership Updates

    See more
    • CENTOGENE Reports First Half 2023 Financial Results

      First half 2023 total revenues with double-digit growth of 15.1% at €24.6 millionBoth Pharma and Diagnostics segments deliver strong performance, reaffirming full year 2023 guidance for total revenue growth between 10% to 15%Recently announced strategic collaboration with Lifera, a biopharmaceutical company wholly-owned by the Saudi Arabia Public Investment Fund (PIF), strengthens global genomic and multiomic footprint and secures CENTOGENE $30 million investment and approx. $50 million in Joint Venture upfront payment and performance-related milestones CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the essential life s

      9/7/23 5:00:52 PM ET
      $CNTG
      Medical Specialities
      Health Care
    • CENTOGENE Announces Approval of All Resolutions Tabled at 2023 Annual General Meeting

      CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 30, 2023 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (NASDAQ:CNTG) (the "Company"), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the voting results of the Company's Annual General Meeting. Shareholders voted in favor of all proposals, which included the appointment of Prof. Dr. Peter Bauer as a member of the Management Board of the Company, as well as the appointment of Mary Sheahan and the reappointment of Peer Schatz as members of the Supervisory Board of the Company. The shareholders extended the period for drawing up the Dutch statutory annual accounts and board report f

      6/30/23 4:30:02 PM ET
      $CNTG
      Medical Specialities
      Health Care
    • CENTOGENE Reports Full Year 2022 Financial Results

      Full Year 2022 total revenues with double-digit growth of 12% at €47.5 million, in line with prior guidanceSignificant expansion of gross profit margin from 32% to 42% and ongoing cost control resulted in significant improvement of net resultsBoth Pharma and Diagnostics segments positioned for strong performance in 2023, guidance of FY2023 total revenue growth between 10% to 15% CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 16, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG) ("we" or the "Company"), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2022,

      5/16/23 6:25:08 PM ET
      $CNTG
      Medical Specialities
      Health Care